We are excited to announce that Benjamin Gerber has joined Metastate as our new Chief Technology Officer (CTO). This addition significantly bolsters our capabilities in advancing synthetic biology and metabolomics research.
Meet Benjamin Gerber
Benjamin holds a MSc in Physics from the University of Bern, with a grade of Insigni Cum Laude (5.65/6). He is a natural problem solver with a keen analytical mind, coupled with a background in physics and a focus on complex systems, data, and AI. He brings a robust skill set, including quantitative analytics, problem-solving, risk and project management.
Role at Metastate
As CTO, Benjamin will lead our technology roadmap, focusing on enhancing product development, data analytics, and AI capabilities. His risk management experience, combined with his expertise in agile methodologies, will play a critical role as we scale our platform.
The Road Ahead
Benjamin’s skill set aligns perfectly with our growth strategy and our commitment to delivering a comprehensive and efficient platform. His experience will be crucial as we work towards the upcoming launch of our Intelligent Suite, featuring advanced Spectra Processing and Generative AI Insights.
We are now a strong team of two co-founders and three full-time employees, geared towards pushing the boundaries in synthetic biology and metabolomics research.
Please join us in warmly welcoming Benjamin to the Metastate team. We are thrilled to see the extraordinary contributions he will undoubtedly bring.